Company Analysis
Sign in

Neurogene Inc. (NGNE)

Nasdaq: NGNE · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.0
◀ Past 4.6● Present 5.2▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Neurogene Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.0/10
◀ Past4.625% of the headline
● Present5.235% of the headline
▶ Future5.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
3.5/10

Has it survived what it has been through?

3 warning events since 2017; the latest 2024-11-14.

weight 22% of this tense · 35th percentile among 497 sector filers · read for itself

From the record

Neurogene Inc.'s filings since 2017 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2022-10-31); an auditor change (8-K item 4.01, the latest 2020-03-20); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-11-14) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
1.4/10

What has it actually done, year after year?

4 filed years; profitable in 0 of 8.

weight 45% of this tense · 14th percentile among 323 sector filers · read for its customers

From the record

Neurogene Inc.'s 4 filed years say what it did: it rose in 0 of 2 years; the deepest fall was 100% from fiscal 2018 to fiscal 2023; net income was positive in 0 of 8 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 4% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
9.8/10

How has it treated the people who own it?

SI estimate 9.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 98th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neurogene Inc.'s shareholder treatment is put at 9.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.2/1035% of the headline grade · 1 of 3 filed, 2 estimated

Financial health

as filed
6.6/10

Is it financially healthy right now?

ROE -34%: lost 34¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.

weight 45% of this tense · 66th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Neurogene Inc. lost about 34 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 21.4% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 12% of its family
  • return on equitytop 37% of its family
  • the share count against the year beforebottom 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate
5.2/10

How strong is its position in its industry?

SI estimate 5.2/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 315 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one.
What the record cannot read
No filed revenue on file.
How it was reasoned
family median, 315 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neurogene Inc.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

SI estimate
3.3/10

What are the people in charge doing?

SI estimate 3.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 33rd percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 33% of 415 in its family; the record of its people begins on 2023-12-26 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2023-12-26 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 415 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neurogene Inc.'s leadership is put at 3.3 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 33% of 415 in its family; the record of its people begins on 2023-12-26 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.0/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
5.9/10

How much room does it have to grow?

SI estimate 5.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 59th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 41% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neurogene Inc.'s room to expand is put at 5.9 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 41% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
5.9/10

What could actually drive growth from here?

top 41% of 306 in its family for growth drivers.

weight 45% of this tense · 59th percentile among 306 sector filers · read for its customers

From the record

Neurogene Inc.'s growth drivers, from the filed years to fiscal 2025: research spending grew 16.4% a year (top 28%); capital spending grew -19% a year (bottom 46%) (its annual reports). Neurogene Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth of research spending16.4%top 28% of its family
  • three-year growth of capital spending-19.0%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
1.7/10

Did its newest year beat what its own record pointed to?

SI estimate 1.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 17th percentile among 284 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the bottom 17% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 284 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neurogene Inc.'s expectations vs reality is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 17% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NGNE · research, not advice